ArticleClinical and translational radiation oncology2026
Patterns of prostate recurrence after focal salvage prostate brachytherapy for radiorecurrent prostate cancer.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Focal high-dose-rate (HDR) salvage brachytherapy has emerged as a treatment for radiorecurrent prostate cancer. This study aims to evaluate patterns of recurrence after focal salvage brachytherapy and to assess the adequacy of current treatment margins. Materials and methods: Between March 2015 and December 2021, 39 patients with radiorecurrent prostate cancer underwent focal HDR brachytherapy. All patients had biopsy-confirmed local recurrence and were staged using Choline- or PSMA-PET/CT and multiparametric MRI. A 5 mm margin around the GTV was applied to define the CTV. Post-treatment recurrences were analyzed using rigid image registration of PET/CT and MRI to assess spatial relationships among the initial recurrence (Rec1), the recurrence following salvage brachytherapy (Rec2), and the brachytherapy dose distribution. The recurrences were categorized into infield, marginal, and outfield based on overlap of relapse with the treated CTV and based on dose received on the site of the relapse. Additionally, spatial analysis measured minimal distances between Rec1 and Rec2. Results: Nineteen of 39 patients experienced clinical recurrence, with 12 exhibiting 25 local lesions. Based on spatial overlap, 20 % of Rec2 lesions were infield, 28 % marginal, and 52 % outfield. Dose-based classification indicated 52 % infield, 8 % marginal, and 40 % outfield recurrence. The median distance between Rec1 and Rec2 in outfield cases was 11.9-13.4 mm. Conclusion: A substantial proportion of local recurrences after focal salvage brachytherapy occur outside the treated volume. Current 5 mm margins may be insufficient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.